-
1.发明授权
公开(公告)号：KR101349198B1
公开(公告)日：2014-01-09
申请号：KR1020087030865
申请日：2006-12-08
Applicant: (주)아모레퍼시픽
IPC: A61K31/661 , C07K14/47 , C12Q1/68 , A61P17/00
CPC classification number: C12Q1/18 , G01N33/92 , G01N2405/08 , G01N2800/202
Abstract: SPC는 아토피성 피부염 환자에게서 인간 베타 디펜신(HBD-1, HBD-2, HBD-3 및 HBD-4), 카텔리시딘(LL-37) 및 덤시딘의 발현을 억제시키므로, SPC 길항제는 AMPs의 발현 감소 관련 질환의 예방 및 치료에 유용하다.
-
公开(公告)号：KR1020080051201A
公开(公告)日：2008-06-11
申请号：KR1020060121861
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/685 , A61K31/661
CPC classification number: A61K31/688 , Y10S514/863 , Y10S514/886
Abstract: A pharmaceutical composition comprising sphingosylphosphorylcholine or derivatives thereof is provided to inhibit proliferation and promote differentiation of keratinocyte, inhibit proliferation of splenocyte and T cell, induce reduction of leucocyte, and reduce mouse ear swelling induced by TPA(tetradecanoyl phorbol acetate), so that the composition is useful for treating psoriasis. A pharmaceutical composition for treating psoriasis comprises sphingosylphosphorylcholine(SPC) represented by the formula(1) or derivatives thereof and is formulated as tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterile injection or sterile powder, wherein the daily dosage is 1-100 mg/kg, preferably 5-70 mg/kg.
Abstract translation: 提供包含鞘氨醇磷酰胆碱或其衍生物的药物组合物，以抑制角质形成细胞的增殖和促进分化，抑制脾细胞和T细胞的增殖，诱导白细胞的减少，并减少TPA（十四酰基佛波醇乙酸酯）诱导的小鼠耳肿胀，使组合物 可用于治疗牛皮癣。 用于治疗牛皮癣的药物组合物包含由式（1）表示的鞘糖基磷酰胆碱（SPC）或其衍生物，并配制成片剂，丸剂，粉末，小药囊，酏剂，悬浮液，乳剂，溶液，糖浆，气雾剂，软或硬明胶胶囊 无菌注射或无菌粉末，其中日剂量为1-100mg / kg，优选5-70mg / kg。
-
公开(公告)号：KR100879411B1
公开(公告)日：2009-01-19
申请号：KR1020060065840
申请日：2006-07-13
Applicant: (주)아모레퍼시픽 , 에스비사이언스(주)
IPC: A61K31/131 , A61P17/02
Abstract: 본 발명은 하기 화학식 1로 표시되는 2-아미노-2-옥틸옥시메틸-프로판-1,3-디올(2-amino-2-octyloxymethyl-propane-1,3-diol, AOOMP) 또는 이의 약학적으로 허용 가능한 염을 포함하는, 스핑고실포스포릴콜린(sphingosylphosphorylcholine, SPC)의 작용을 억제하는 약학 조성물에 관한 것이다.
본 발명에 따른 약학 조성물은 SPC의 생체내 및 생체외 작용에 따른 세포 분열 증식, 염증 반응, 히스타민 분비 또는 가려움증 등을 효과적으로 억제하고, 투여시 심장 박동수의 저하와 같은 부작용이 없으므로, 외상 후의 흉터 형성 억제 및 아토피성 피부염 또는 기타 질환에서 나타나는 염증, 소양증, 및 피부 감염증 등의 예방 및 치료에 유용하게 사용될 수 있다.-
公开(公告)号：KR1020080006737A
公开(公告)日：2008-01-17
申请号：KR1020060065840
申请日：2006-07-13
Applicant: (주)아모레퍼시픽 , 에스비사이언스(주)
IPC: A61K31/131 , A61P17/02
Abstract: A pharmaceutical composition is provided to effectively inhibit cell proliferation, inflammatory reaction, histamine secretion or itch caused by the function of sphingosylphosphorylcholine without side effects, thereby being usefully used for inhibiting scar formation after wound and preventing and treating inflammation, pruritus and skin inflammatory diseases. A pharmaceutical composition for inhibiting the function of sphingosylphosphorylcholine comprises 2-amino-2-octyloxymethyl-propane-1,3-diol represented by the formula(1) or a pharmaceutically acceptable salt thereof. The composition further comprises a carrier, an excipient or a diluent.
Abstract translation: 提供药物组合物以有效地抑制由鞘脂酰磷酰胆碱的功能引起的细胞增殖，炎症反应，组胺分泌或瘙痒，无副作用，从而有效地用于抑制伤口后的瘢痕形成，预防和治疗炎症，瘙痒和皮肤炎症性疾病。 用于抑制鞘糖基磷酰胆碱功能的药物组合物包含由式（1）表示的2-氨基-2-辛氧基甲基 - 丙烷-1,3-二醇或其药学上可接受的盐。 组合物还包含载体，赋形剂或稀释剂。
-
公开(公告)号：KR1020080050786A
公开(公告)日：2008-06-10
申请号：KR1020060121508
申请日：2006-12-04
Applicant: (주)아모레퍼시픽
IPC: A61K31/133
Abstract: A method for inducing itch and a method for screening an itch inhibiting material using glucosylsphingosine are provided to be useful for studying and understanding the itch, thereby being very usefully used for developing a therapeutic agent for the itch and evaluating the effect of a medicine. A method for inducing itch comprises a step of administering at least one compound selected from the group consisting of glucosylsphingosine and a derivative thereof into an animal except human. A method for screening an itch inhibiting material comprises the steps of: (a) administering an itch inhibition candidate material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A method for evaluating the itch inhibition effect comprises the steps of: (a) administering an itch inhibition material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A composition for inducing itch comprises at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof as an effective ingredient.
Abstract translation: 提供诱导瘙痒的方法和使用葡糖基鞘氨醇来筛选瘙痒抑制物质的方法，可用于研究和理解瘙痒，从而非常有用地用于开发瘙痒治疗剂并评估药物的效果。 诱导瘙痒的方法包括向除人之外的动物中施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物的步骤。 筛选瘙痒抑制物质的方法包括以下步骤：（a）通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物，向瘙痒诱导的动物施用瘙痒抑制候选物质; 和（b）当动物划伤时计数。 评估瘙痒抑制效果的方法包括以下步骤：（a）向通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物诱导瘙痒的动物施用瘙痒抑制物质; 和（b）当动物划伤时计数。 用于诱导瘙痒的组合物包含至少一种选自葡糖基鞘氨醇及其衍生物的化合物作为有效成分。
-
Patent Agency Ranking
公开(公告)号：KR1020080034575A
公开(公告)日：2008-04-22
申请号：KR1020060100703
申请日：2006-10-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/047 , A61K31/13
CPC classification number: A61K31/047
Abstract: A method for inhibiting the expression of CCL27/CTACK(Cutaneous T-cell-attracting chemokine) is provided to regulate SPC(sphingosylphosphorylcholine) inducing expression of CCL27/CTACK, so that the method is useful for prevention and treatment of diseases associated with overexpression of CCL27/CTACK including atopic dermatitis, psoriasis and inflammatory skin disease. The expression of CCL27/CTACK is inhibited by administering an effective amount of sphingosylphosphorylcholine regulator capable of inhibiting activity of SPC or competing with the mechanism of SPC inducing overexpression of CCL27/CTACK to a mammal requiring the expression reduction of CCL27/CTACK. A method for screening the SPC regulator comprises the steps of: (1) treating a testing cell such as keratinocyte with 2-10 muM of SPC or its derivatives to induce overexpression of CCL27/CTACK; and (2) treating the overexpression of CCL27/CTACK-induced cell with a candidate material and measuring the expression inhibition of CCL27/CTACK. Further, the mammal has an atopic dermatitis or psoriasis.
Abstract translation: 提供抑制CCL27 / CTACK（皮肤T细胞吸引趋化因子）表达的方法，以调节诱导CCL27 / CTACK表达的SPC（鞘氨醇磷酰胆碱），从而该方法可用于预防和治疗与过表达相关的疾病 CCL27 / CTACK包括特应性皮炎，牛皮癣和炎性皮肤病。 通过施用有效量的能够抑制SPC活性或与诱导CCL27 / CTACK过表达的SPC的机制竞争需要CCL27 / CTACK表达降低的哺乳动物，CCL27 / CTACK的表达被抑制。 用于筛选SPC调节剂的方法包括以下步骤：（1）用2-10μM的SPC或其衍生物处理测试细胞如角质细胞，以诱导CCL27 / CTACK的过度表达; 和（2）用候选物质治疗CCL27 / CTACK诱导的细胞的过度表达，并测量CCL27 / CTACK的表达抑制。 此外，哺乳动物具有特应性皮炎或牛皮癣。
-
公开(公告)号：KR1020070107961A
公开(公告)日：2007-11-08
申请号：KR1020060040588
申请日：2006-05-04
Applicant: (주)아모레퍼시픽
IPC: A61K36/9068 , A61K36/754
CPC classification number: A61K36/00 , A61K8/97 , A61K9/00 , A61K36/754 , A61K36/9062 , A61K36/9068 , A61K2236/33 , A61Q19/00 , A61Q19/005 , Y10S514/857
Abstract: A composition comprising extracts of crude drugs is provided to suppress and relieve itching caused by inflammatory and atopic dermatitis without side effects such as toxicity and skin irritation. A composition for suppressing and relieving itching comprises 0.1-10 wt.% of the extracts of Zingiber officinale Rosc., Evodia officinalis and Alpinia katsumadai Hayata which are prepared by extracting them with water, C1-C4 lower alcohol or a mixed solvent thereof. The daily dosage of crude drug extracts is 0.001-100 mg/kg, preferably 0.1-30 mg/kg and the composition is a pharmaceutical composition having a formulation selected from ointment, plaster, lotion and liniment, or a cosmetic composition having a formulation selected from skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
Abstract translation: 提供包含生药提取物的组合物以抑制和缓解由炎性和特应性皮炎引起的瘙痒，而没有副作用，例如毒性和皮肤刺激。 用于抑制和缓解瘙痒的组合物包括通过用水，C1-C4低级醇或其混合溶剂提取它们制备的姜黄提取物的0.1-10重量％的提取物。 生药提取物的日剂量为0.001-100mg / kg，优选0.1-30mg / kg，并且组合物是具有选自软膏，石膏，洗剂和搽剂的制剂的药物组合物或具有选择的制剂的化妆品组合物 从皮肤洗剂，皮肤柔肤剂，皮肤调色剂，收敛剂，乳液，乳液，滋润乳液，营养乳液，按摩霜，营养霜，保湿霜，护手霜，粉底，精华，营养精华，包装，肥皂，清洁泡沫，清洁 洗剂，清洁霜，身体乳液和身体清洁剂。
-
8.发明授权헥소사민 화합물 또는 이의 약학적으로 허용 가능한 염을포함하는, 수술 후 유착의 예방 또는 치료용 약학 조성물 有权用于预防或治疗包含十四烷基胺化合物或其药学上可接受的药物的术后粘合剂的药物组合物
公开(公告)号：KR101349200B1
公开(公告)日：2014-01-09
申请号：KR1020060121432
申请日：2006-12-04
Applicant: (주)아모레퍼시픽
IPC: A61K31/351 , A61P41/00
Abstract: 본 발명은 활성성분으로서 하기 화학식 1의 헥소사민 화합물 및 이의 약학적으로 허용가능한 염을 포함하는, 수술 후 유착증 (Post-operative adhesion)의 예방 또는 치료용 약학 조성물에 관한 것으로, 본 발명의 조성물에 포함된 헥소사민 화합물 또는 이의 약학적으로 허용 가능한 염은 복강에서 섬유소성 장 유착을 유발시킨 쥐 (rat) 모델에서 우수한 장 유착 저해활성을 나타내므로, 각종 외과적 수술 후 유발되는 부작용 중 하나인 섬유소성 장 유착 병증을 예방 또는 치료하는 데 유용하게 사용될 수 있다.
-
公开(公告)号：KR101349188B1
公开(公告)日：2014-01-08
申请号：KR1020060100703
申请日：2006-10-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/047 , A61K31/13
CPC classification number: A61K31/047
Abstract: 본 발명은 스핑고실포스포릴콜린 (sphingosylphosphorylcholine; SPC)의 조절제 (modulator)를 이용하여 CCL27/CTACK (Cutaneous T-cell-attracting chemokine)의 발현을 억제시키는 방법 및 CCL27/CTACK 발현의 억제정도를 측정하여 SPC의 조절제 후보 물질을 스크리닝하는 방법에 관한 것으로, SPC가 아토피 피부염, 건선 및 염증성 피부 질환 환자들에서 발현 증가 양상을 보이고 있는 CCL27/CTACK의 발현을 증가시키므로, 본 발명에 따라 SPC 조절제를 투여하여 CCL27/CTACK의 발현을 억제시킴으로써 CCL27/CTACK 발현 증가 관련 질환의 치료 및 예방 효과를 얻을 수 있으며, CCL27/CTACK 유전자 또는 이들 단백질의 발현 억제 정도를 분석하여 SPC 조절제를 효율적으로 검색 (screening)할 수 있다.
-
10.发明公开
公开(公告)号：KR1020090016595A
公开(公告)日：2009-02-16
申请号：KR1020087030865
申请日：2006-12-08
Applicant: (주)아모레퍼시픽
IPC: A61K31/661 , C07K14/47 , C12Q1/68 , A61P17/00
CPC classification number: C12Q1/18 , G01N33/92 , G01N2405/08 , G01N2800/202 , A61K31/661 , C07K14/47
Abstract: A sphingosylphosphorylcholine(SPC) antagonist is provided to prevent and treat diseases related to the expression decrease of anti-bacterial peptide such as atopic dermatitis, and screen the SPC antagonist by analyzing the expression recover of gene or protein of the anti-bacterial peptide. The sphingosylphosphorylcholine(SPC) antagonist manufactures the medicine for restoring the expression of anti-bacterial peptide back to the normal level in mammal requiring the expression restoration of anti-bacterial peptide. The screening method of the sphingosylphosphorylcholine(SPC) antagonist comprises the steps of: treating the object with sphingosylphosphorylcholine or its derivative to inhibit expression of anti-bacterial peptide; and treating the object with the SPC antagonist candidate material, and analyzing the expression restoration level of the anti-bacterial peptide in the object.
Abstract translation: 提供鞘糖基磷酰胆碱（SPC）拮抗剂以预防和治疗与抗细菌肽如特应性皮炎的表达降低相关的疾病，并通过分析抗细菌肽的基因或蛋白质的表达恢复来筛选SPC拮抗剂。 鞘氨醇磷酰胆碱（SPC）拮抗剂在需要抗菌肽表达恢复的哺乳动物中制备了将抗菌肽的表达恢复至正常水平的药物。 鞘氨醇磷酰胆碱（SPC）拮抗剂的筛选方法包括以下步骤：用鞘糖基磷酰胆碱或其衍生物处理物体以抑制抗菌肽的表达; 并用SPC拮抗剂候选物质处理对象，分析对象中抗菌肽的表达恢复水平。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.021 seconds)
